Top

Published in:

01-12-2023 | Ritonavir | News item

Paxlovid: risk of drug interactions

Published in: Reactions Weekly | Issue 1/2023

Excerpt

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is advising healthcare professionals that there is a risk of potentially harmful drug interactions with the ritonavir component of the COVID-19 treatment Paxlovid (nirmatrelvir+ritonavir) due to its inhibition of the enzyme CYP3A4, which metabolises many commonly used drugs and may lead to increased toxicity from concomitant medications or reduced effectiveness of Paxlovid. …

Nirmatrelvir, ritonavir (Paxlovid): be alert to the risk of drug interactions with ritonavir Internet Document : 23 Nov 2023. Available from: URL: https://www.gov.uk/drug-safety-update/nirmatrelvir-ritonavir-paxlovidv-be-alert-to-the-risk-of-drug-interactions-with-ritonavir

Title: Paxlovid: risk of drug interactions
Publication date: 01-12-2023
Publisher: Springer International Publishing
Keyword: Ritonavir
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-50774-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Paxlovid: risk of drug interactions

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Epinephrine

Pembrolizumab

FDA warns against use of Neptune's Fix due to severe AEs

Dabrafenib/trametinib

Amiodarone

Camrelizumab